TNFRSF1A and metabolic dysfunction-associated steatotic liver disease: Using network pharmacology and in vivo experiments, this research revealed that CSP may have the capacity to effectively alleviate hepatic steatosis in the progression of NAFLD and inhibit the inflammatory response through the TNFα/TNFR1 signaling pathway, which also paves the way for the specific molecular mechanism of CSP in NAFLD.